Title and Organization:
Camille Samuels joined Venrock in 2014, bringing years of venture capital and operating experience, and a deep network, to her portfolio companies. She specializes in early-stage biotechnology, consumer health, and medical device investing and enjoys helping talented entrepreneurs build exceptional companies. Prior to Venrock, Cami spent 12 years as a Managing Director at Versant Ventures. Cami joined Versant in early 2000, shortly after its formation. Prior to Versant, she was responsible for business development at Tularik, Inc. (subsequently acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik's Technology Acquisition Group. Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting. Cami's notable investments include Achaogen (AKAO), Kythera (KYTH/acquired by Allergan), NovaCardia (acquired by Merck), Regenix (RGNX), ParAllele (acquired by Affymetrix) and Unity (UBX). In addition, she served as a board observer at several companies, including Alexza (public), Fluidigm, Genomic Health (public) and Syrrx (acquired by Takeda). Cami earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. Cami is a 2002 Henry Crown Fellow of The Aspen Institute and a member of the Aspen Global Leadership Network.